Biggest News Aggregation in the World
📰 Nasdaq Edit News

Page 3 - Nasdaq Edit News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.

Brave Asset Management Inc. Purchases Shares of 10,725 Editas Medicine, Inc. (NASDAQ:EDIT)

Brave Asset Management Inc. acquired a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,725 shares of the company’s stock, valued at approximately $88,000. A number of other hedge funds have also modified […]
United Kingdom Baisong Mei Raymond James Cambridge Investment Research Advisors Inc Mercer Global Advisors Inc Patriot Financial Group Insurance Agency

Stifel Nicolaus Upgrades Editas Medicine (NASDAQ:EDIT) to Buy

Stifel Nicolaus upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a hold rating to a buy rating in a report published on Thursday morning, Marketbeat reports. They currently have $17.00 target price on the stock, up from their prior target price of $9.00. Other equities research analysts have also recently issued research reports […]
Raymond James Stifel Nicolaus Baisong Mei Editas Medicine Company Profile Congress Asset Management Co Silicon Hills Wealth Management

Editas Medicine (NASDAQ:EDIT) Rating Increased to Buy at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a hold rating to a buy rating in a report released on Thursday morning, MarketBeat.com reports. They currently have $17.00 target price on the stock, up from their previous target price of $9.00. A number of other research analysts have also weighed in […]
Raymond James Baisong Mei Stifel Nicolaus Editas Medicine Inc Cantor Fitzgerald Securities Exchange Commission
Source: wkrb13.com

Editas Medicine (NASDAQ:EDIT) vs. Autolus Therapeutics (NASDAQ:AUTL) Head-To-Head Comparison

Editas Medicine (NASDAQ:EDIT – Get Free Report) and Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Institutional & Insider Ownership 76.6% of Editas […]
United Kingdom United States City Of Allergan Pharmaceuticals International Gengine Inc Editas Medicine Inc
Source: wkrb13.com

125,742 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Acquired by Profund Advisors LLC

Profund Advisors LLC purchased a new position in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 125,742 shares of the company’s stock, valued at approximately $912,000. Profund Advisors LLC owned 0.18% of Editas Medicine at the […]
Raymond James Gilmore Neil Oneill Baisong Mei Financial Services Group Inc Securities Exchange Commission Cantor Fitzgerald

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Editas Medicine (NASDAQ:EDIT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report released on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the subject of a number of other research reports. Oppenheimer reissued a market perform rating and set a $12.00 price objective on shares of […]
Raymond James Gilmore Neil Oneill Baisong Mei Topco Ltd Editas Medicine Inc Securities Exchange Commission
Source: wkrb13.com

Editas Medicine (NASDAQ:EDIT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the topic of a number of other research reports. Raymond James upgraded Editas Medicine from a market perform rating to an outperform rating and […]
Baisong Mei Gilmore Neil Oneill Raymond James Covestor Ltd Allspring Global Investments Holdings Securities Exchange Commission

FY2023 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Lifted by Cantor Fitzgerald

Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Cantor Fitzgerald upped their FY2023 earnings estimates for Editas Medicine in a report issued on Tuesday, August 8th. Cantor Fitzgerald analyst R. Bienkowski now forecasts that the company will post earnings per share of ($2.35) for the year, up from their prior estimate of ($2.43). […]
Gilmore Neil Oneill Baisong Mei Cantor Fitzgerald Raymond James Headlands Technologies Allspring Global Investments Holdings

Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer restated their market perform rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $12.00 price target on the stock. EDIT has been the subject of a number of other research reports. StockNews.com lowered Editas Medicine from a hold […]
Baisong Mei Gilmore Neil Oneill Raymond James Congress Asset Management Co Dimensional Fund Advisors Silicon Hills Wealth Management
Source: wkrb13.com

Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $19.00

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective cut by Chardan Capital from $22.00 to $19.00 in a report published on Wednesday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. EDIT has been the topic of a number of other reports. Raymond James upgraded shares of Editas Medicine […]
Gilmore Neil Oneill Baisong Mei Raymond James Dimensional Fund Advisors Securities Exchange Commission Editas Medicine Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science